Guillain-Barré Syndrome Related to Nivolumab: Case Report of a Patient With Urothelial Cancer and Review of the Literature

Clin Genitourin Cancer. 2019 Apr;17(2):e360-e364. doi: 10.1016/j.clgc.2018.11.022. Epub 2018 Dec 4.

Authors

Anastasios Kyriazoglou¹, Michael Liontos², Costantinos Papadopoulos³, Afroditi Bilali², Euthymios Kostouros², Stamatina Pagoni⁴, Konstantinos Doumas⁵, Meletios Athanasios Dimopoulos², Aristotelis Bamias²

Affiliations

¹ Department of Clinical Therapeutics, Alexandra Hospital, Athens, Greece. Electronic address: tassoskyr@gmail.com.
² Department of Clinical Therapeutics, Alexandra Hospital, Athens, Greece.
³ 1st Department of Neurology, Aiginiteio Hospital, Athens, Greece.
⁴ 3rd Department of Internal Medicine, General Hospital of Athens "G. Gennimatas", Athens, Greece.
⁵ Department of Urology, General Hospital of Athens "G. Gennimatas", Athens, Greece.

PMID: 30612920
DOI: 10.1016/j.clgc.2018.11.022

No abstract available

Keywords: Guillain-Barré syndrome; Immune related adverse effects; Immune-related toxicity; Nivolumab; Toxicity.

Publication types

Case Reports

MeSH terms

Aged
Carcinoma, Transitional Cell / drug therapy
Fatal Outcome
Guillain-Barre Syndrome / chemically induced*
Guillain-Barre Syndrome / drug therapy
Humans
Immunoglobulins, Intravenous / therapeutic use
Male
Nivolumab / adverse effects*
Prednisone / therapeutic use
Urologic Neoplasms / drug therapy

Substances

Immunoglobulins, Intravenous
Nivolumab
Prednisone